8-K current report · filed Aug 13, 2026

MapLight Therapeutics, Inc. (MPLT) 8-K Current Report: August 13, 2026

Item 1.01Item 3.02Item EX-99.1Item EX-99.2Item EX-99.3Item 7.01Item 2.02MPLT overview

Short answer

MapLight Therapeutics, Inc. (MPLT) filed an 8-K current report with the SEC on August 13, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 3.02 (Unregistered Sales of Equity Securities), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item EX-99.3 (Exhibit EX-99.3), Item 7.01 (Regulation FD Disclosure), Item 2.02 (Results of Operations and Financial Condition). $150.0 million gross private placement, strengthening funding for MapLight’s operations and development programs.

MapLight Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • $150.0 million gross private placement, strengthening funding for MapLight’s operations and development programs
  • 9,197,887 common shares plus pre-funded warrants for 3,983,168 shares at $11.38 per share, creating substantial dilution
  • Pre-funded warrants carry $0.0001 exercise prices and do not expire, making eventual dilution highly likely
  • Resale registration due within 30 days after closing, with 1.0% liquidated damages per 30-day delay, subject to caps
  • Morgan Stanley, Jefferies, Leerink Partners and Stifel serving as placement agents, with fees and expense reimbursements reducing net proceeds

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 results covered quarter ended June 30, 2026, with full results in Exhibit 99.1
  • Cash, cash equivalents and investments totaled $351.3 million at June 30, 2026
  • $150 million private placement announced, providing additional financing capacity
  • Investors should assess dilution and updated liquidity runway using Exhibit 99.2 terms

Item 3.02 · Unregistered Sales of Equity Securities

  • Unregistered securities issued in a private placement under Securities Act Section 4(a)(2)
  • Securities subject to resale restrictions absent registration or another exemption
  • Transaction avoided public offering, general solicitation and general advertising
  • Investors should review Item 1.01 for the securities issued and purchase agreement terms

Item 7.01 · Regulation FD Disclosure

  • Updated corporate presentation signals refreshed investor messaging and potentially new clinical, pipeline, or corporate milestones
  • Presentation available on MapLight Therapeutics’ website and furnished as Exhibit 99.3
  • Investors should review Exhibit 99.3 for substantive updates affecting valuation or development expectations

Item EX-99.1 · Exhibit EX-99.1

  • Positive Phase 2 ZEPHYR results support planned registrational Phase 3 ZEPHYR-2 in schizophrenia, with topline results expected in 2028
  • ML-007C-MA advanced as the lead asset across schizophrenia and ADP; VISTA enrollment ongoing with results expected in the second half of 2027
  • ML-004 missed its primary ASD social-communication endpoint, shifting focus toward adolescent irritability and potential partnerships or funding
  • Cash, equivalents and investments of $351.3M plus a $150M private placement expected to fund ML-007C-MA programs through 2028
  • Second-quarter net loss widened to $60.2M from $29.8M, while R&D expense rose to $53.4M from $26.8M

Item EX-99.2 · Exhibit EX-99.2

  • $150M PIPE financing, strengthening liquidity for late-stage clinical development
  • 9,197,887 shares sold at $11.38, plus pre-funded warrants for 3,983,168 shares
  • Proceeds targeted to VISTA Phase 2 and ZEPHYR-2 Phase 3 studies for ML-007C-MA
  • Cash, equivalents and investments totaled $351.3M at June 30, 2026
  • Management expects funding through 2028, subject to operational assumptions and clinical execution

Item EX-99.3 · Exhibit EX-99.3

  • August 13 presentation highlights ML-007C-MA as MapLight’s lead asset, with schizophrenia Phase 3 planning and Alzheimer’s disease psychosis results expected in 2H 2027
  • ZEPHYR Phase 2 met its primary endpoint, PANSS effect size 0.37 mITT and 0.50 among completers, supporting planned registrational development
  • Prespecified cognitive endpoint improved, effect size 0.51 and p=0.041, potentially differentiating ML-007C-MA in a major unmet-need area
  • Tolerability profile supports commercial positioning, 99% reached target dose and 7.1% discontinued for treatment-emergent adverse events
  • Cash of approximately $501M, including $150M gross private-placement proceeds, extends stated runway through 2028

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other MapLight Therapeutics, Inc. 8-K filings

Get the next MPLT 8-K as it lands

Follow MPLT for push alerts, or ask the research agent what this filing means.